Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 845.81M P/E - EPS this Y 25.20% Ern Qtrly Grth -
Income -597.65M Forward P/E -2.34 EPS next Y 14.00% 50D Avg Chg -28.00%
Sales 1.31M PEG 2.66 EPS past 5Y - 200D Avg Chg -46.00%
Dividend N/A Price/Book N/A EPS next 5Y -1.70% 52W High Chg -75.00%
Recommedations 2.00 Quick Ratio 3.54 Shares Outstanding 696.53M 52W Low Chg 60.00%
Insider Own 77.04% ROA -61.04% Shares Float 165.47M Beta -0.34
Inst Own 9.14% ROE - Shares Shorted/Prior 50.74M/49.18M Price 1.94
Gross Margin 100.00% Profit Margin - Avg. Volume 4,291,806 Target Price 6.38
Oper. Margin -9,487.39% Earnings Date Nov 6 Volume 2,707,031 Change -4.90%
About ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

ImmunityBio, Inc. News
11/20/24 High Growth Tech Stocks To Watch In November 2024
11/19/24 ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
11/12/24 ImmunityBio Reports Third-Quarter 2024 Financial Results
10/25/24 ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?
10/24/24 First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
08:00 AM ImmunityBio to Participate in the Jefferies London Healthcare Conference
09/09/24 ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
08/12/24 ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
08/06/24 ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
07/31/24 Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop
06/20/24 ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
06/07/24 ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
05/17/24 Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
05/11/24 ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
05/07/24 ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
05/02/24 ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
04/30/24 ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
04/24/24 ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
04/23/24 ImmunityBio's bladder cancer therapy wins FDA approval
04/22/24 ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
IBRX Chatroom

User Image Kopelius Posted - 1 hour ago

$IBRX Being positive, we are above last week price and 39% above last month. Plese, no more good news for today!! let me recover my liver...

User Image YorkMeister Posted - 1 hour ago

$IBRX

User Image GreenRaccoon Posted - 3 hours ago

Fyi: @PhoenixLights @anktiva i heard somewhere unrelated to $ibrx, that subscriber # means dar less to the YouTube algo than likes and shared links.

User Image Edddddd Posted - 4 hours ago

$IBRX I have to laugh at all the newbies marveling at the volatility of this ticker. It will kick you in the balls for 30 days straight and then pump for days on end, sometimes for no reason at all. I’ve only been here since just post CRL, I’m sure there are plenty of OG’s here many years before that. This ticker is a motherfucker, just when you think you have it figured out you realize you don’t. When it wants to run it runs hard, but it will also break your heart more times than not. Holding some for the big one, but no idea when that will come.

User Image BixbyKnolls Posted - 4 hours ago

$IBRX - So much revealed yesterday--/ Transformative - The new focus with the great data on PSA drop Prostrate. Such BS the phony walk down to get shares taken. 🚀💯🥳

User Image IBRX_Whale Posted - 5 hours ago

$IBRX - I have 3400 shares currently. If this hits $4.50 I will purchase another 2600 to get to 6,000.

User Image KissMyAngus02 Posted - 5 hours ago

@Xposed $ibrx the $400-500mil could easily come fr a partnership agmt. depends on the royalty negotiated.

User Image IBEnergized Posted - 5 hours ago

$IBRX I just have a funny feeling this will continue the drop for weeks as there doesn’t promise to be any news until January. Jeffries was the big chance to announce something big and they missed. Shorts know what they are doing once again.

User Image Biofrog Posted - 5 hours ago

$IBRX The slide showed I think 15 check point inhibitors. And we can give them 8 more years of patent life. And we double their survival so we double their sales. And the projected market is 148bill.

User Image legend_217 Posted - 5 hours ago

$IBRX of course it’s always pump and dump

User Image KissMyAngus02 Posted - 6 hours ago

@Biofrog disagree. i think pharma w a CPI turbo charges sales. and fr their standpoint, it takes one "competitor" off the board if you believe bcg is their competition. (at least in the bladder cancer space) $ibrx

User Image bike_it_59 Posted - 6 hours ago

$IBRX https://www.youtube.com/watch?v=0bsVWXZbHH4 feedback from LUGPA conference for 2024 approvals and whats the competition is doing for NMIBC space in 2025 for both unresponsive and naive populations

User Image NCDave Posted - 7 hours ago

$IBRX Just watched the Jefferies chat. Sorry if this was discussed earlier... On the capital allocation question, did JSS say significant operational funding would come from 2025 Anktiva sales being $400-500m and then I think he said $200-300m (net income?)? I thought this was well over 2025 consensus. Good to hear about exploring partnership for non US as there is a lot of exciting research to fund.

User Image MN009 Posted - 7 hours ago

$IBRX don’t understand why IBRX stock price rose to around 5.30 ..and today down 10% with no news. What’s going on?

User Image PhoenixLights Posted - 8 hours ago

$IBRX 9 to 72 subscribers in less than 24 hrs. We can do better! Subscribe and share, often. https://youtube.com/@anktiva?si=NMvMfguEnf858SFF

User Image Paul4321 Posted - 8 hours ago

$IBRX SP depression does not equate to technology not working. They are two separate things. For the SP manipulation that is something that happens all the time with small biotechs. It’s the merry go round with Tutes, MMs, and HFs. They work hand in hand though they all have separate goals. Having Tutes buying isnt always a good thing. They are lending those shares to lower their average and to buy more of companies with potential while retail gets scammed. The technology works. Just wait.

User Image Biofrog Posted - 8 hours ago

$IBRX I see the possibility of a few different partner arrangements. Our immediate need is a partner to help us X-US for Bladder/urology to build worldwide bladder sales. We don't need a CPI partner for that. BCG is our CPI there. Does our immediate Bladder partner need to have a CPI thing for the future? It might make the partner more interested if they "get in" with IBRX. Maybe develop a bond. But our bladder partner could be different than our CPI partner(s).

User Image bike_it_59 Posted - 8 hours ago

$IBRX https://www.sciencedaily.com/releases/2024/11/241118125040.htm you never know when a clinical trial from out in left field is going to hit a home run. use of the high dose IV Vitamin C also had significant survival results in Glioblastoma... and of course there's an ongoing NSCLC trial that's expected to read out sometime in '25 Quilt 88 cohort 3 for third line and later pancreatic Cancer trial had an OS rate of roughly 6 months, yet the trial above uses 8 months for OS while IB used 3 months??? and Soon broached the possibility of getting EUA from the FDA, which FDA never even considered

User Image Clau_PR Posted - 9 hours ago

$IBRX we are one of the top 20 tickers with more shares SHORT. Take that into consideration. I am still waiting for the partnership deal so the shorts get scare and start covering...

User Image PatSoonDiggler Posted - 9 hours ago

$IBRX as long investor, I have the distinct impression that PSS is doing what he can to get our share price to the level forecasted by EF Hutton before he raises more capital. At $30 a share or anywhere near that, we won’t feel nearly as much pain.

User Image STLMO Posted - 9 hours ago

$IBRX is definitely manipulated. Mid morning yesterday Zack’s a respectable research firm put a buy out on IBRX. I did not however see a price objective. Zack’s has very good fundamental research. Drip drip another piece of good news

User Image phil4 Posted - 10 hours ago

$IBRX 5 million shares traded that’s better than it was a few months ago by far

User Image Dmck9 Posted - 11 hours ago

$IBRX had a chance to listen to Jeffries London conference… for the life of me, cannot fathom how this is not at least a $17 dollar stock at this point.. I am in the health industry on biotech side and cannot think of another technology platform as promising as IBRX’s… hang tough.. our time is coming…

User Image albiegf13 Posted - 11 hours ago

$IBRX OUCH...! I'm butt hurt...!

User Image Pajohnamo Posted - 12 hours ago

$ACRS looking like another leg up here soon. $7-$12. $DRUG $IBRX $TNXP

User Image The_Claw Posted - 12 hours ago

$IBRX Added. Nice opportunity to average down.

User Image CattyKat Posted - 12 hours ago

$IBRX along for the ride

User Image PaulyRad Posted - 13 hours ago

$IBRX finishing green today

User Image Pumpthendump Posted - 13 hours ago

$IBRX how’s the chronic money suck today? Everyone losing their a$$ as usual here?

User Image IBEnergized Posted - 13 hours ago

$IBRX the future is near https://endpts.com/what-is-the-future-of-the-trump-admins-pharmaceutical-policies/

Analyst Ratings
Piper Sandler Neutral Aug 19, 24
Piper Sandler Neutral Apr 29, 24
Piper Sandler Neutral Mar 25, 24
Piper Sandler Neutral May 12, 23
Jefferies Buy Aug 3, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
BLASZYK MICHAEL D Director Director Jun 05 Buy 2.75 71,915 197,766 71,915 06/05/23
Adcock Richard CEO & President CEO & President Oct 08 Buy 8.9 1,930 17,177 1,930 10/08/21
Cohen Cheryl Director Director Aug 19 Sell 10.08 45,531 458,952 225,394 08/19/21